Legend Biotech Corp (LEGN)
45.37
-0.54
(-1.18%)
USD |
NASDAQ |
May 03, 15:21
Legend Biotech Cash from Investing (Quarterly): 407.51M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 407.51M |
| September 30, 2023 | -209.07M |
| June 30, 2023 | -123.58M |
| March 31, 2023 | 17.93M |
| December 31, 2022 | 24.93M |
| September 30, 2022 | 127.89M |
| June 30, 2022 | 2.585M |
| March 31, 2022 | -232.50M |
| December 31, 2021 | 96.51M |
| September 30, 2021 | -105.67M |
| Date | Value |
|---|---|
| June 30, 2021 | -168.67M |
| March 31, 2021 | -17.15M |
| December 31, 2020 | 61.16M |
| September 30, 2020 | -58.62M |
| June 30, 2020 | -9.212M |
| March 31, 2020 | -17.50M |
| December 31, 2019 | 113.45M |
| September 30, 2019 | -21.19M |
| June 30, 2019 | -36.03M |
| March 31, 2019 | -114.88M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-232.50M
Minimum
Mar 2022
407.51M
Maximum
Dec 2023
-7.749M
Average
-17.15M
Median
Mar 2021
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -464.00M |
| Bristol-Myers Squibb Co | -19.62B |
| 2seventy bio Inc | 47.89M |
| Exelixis Inc | 111.79M |
| Alnylam Pharmaceuticals Inc | -240.66M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -95.64M |
| Cash from Financing (Quarterly) | 0.925M |
| Free Cash Flow | -416.00M |
| Free Cash Flow Per Share (Quarterly) | -0.5635 |
| Free Cash Flow to Equity (Quarterly) | -107.92M |
| Free Cash Flow to Firm (Quarterly) | -102.49M |
| Free Cash Flow Yield | -5.21% |